ArticleExperimental & molecular medicine2025
Loss of PCAF in proximal tubular cells exacerbates renal fibrosis by promoting partial epithelial-to-mesenchymal transition.
Article in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deficiency of GCN5 exacerbates pulmonary fibrosis by disrupting the LKB1-AMPK pathway.Cell communication and signaling : CCS · 2026Article
- Fibrillin-1 Orchestrates a Pro-senescent Niche Driving Peritubular Endothelial Senescence via ZEB1/endothelin-1/β-catenin Signaling.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Renal fibrosis is a consequence of chronic kidney disease, which is estimated to affect 10-14% of the global population. The molecular mechanisms in the pathogenesis of renal fibrosis are still unclear, and there is a lack of effective therapies. Here we identified decreased levels of p300/CBP-associated factor (PCAF) in kidney tissues with fibrosis and demonstrated that PCAF-specific knockout in proximal tubular cells accelerates renal fibrosis in both unilateral ureteral obstruction surgery and folic acid-induced models. Conversely, overexpressing PCAF in the kidney using adenovirus mitigated unilateral ureteral obstruction-induced renal fibrosis. Importantly, PCAF inhibits the epithelial-to-mesenchymal transition of proximal tubular cells by transcriptionally activating adherens junction genes. Moreover, we observed that TGF-β signaling induces lysosomal degradation of PCAF, suggesting that PCAF reduction is affected in the fibrotic milieu. These findings confirm that PCAF is a negative regulator of renal fibrosis and suggest that it could serve as a novel therapeutic target for patients with chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.